4 Feb 2016 07:00
Instem plc("Instem" or the "Company")
Director Shareholding
Instem (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, was notified yesterday of the following deals in the ordinary shares of 10 pence each in the Company ("Ordinary Shares") by David Gare, Chairman.
David Gare is a trustee of the 'The DG 2008 Discretionary Settlement' (the "Trust") which on 3 February 2016 transferred 50,000 Ordinary Shares to each of two beneficiaries, Michael Adrian Gare and Deborah Jane Walker, at nil cost (the "Transaction").
Following the Transaction, the notifiable interest of David Gare is 2,018,427 Ordinary Shares, representing 15.5% of the Company's issued Ordinary Shares. Such shares are all held by the Trust.
For further information, please contact:
Instem plc | +44 (0) 1785 825 600 |
Phil Reason, CEO | |
Nigel Goldsmith, CFO | |
N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
Richard Lindley James White | |
Walbrook Financial PR | +44 (0) 20 7933 8000 |
Paul Cornelius | instem@walbrookpr.com |
Helen Cresswell Sam Allen | |
About Instem plc
Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem supports over 400 clients through full service offices in the United States, the United Kingdom, India and China, with additional presence in France and Japan.
To learn more about Instem solutions and its mission, please visit www.instem.com
INS.L (INS)